MiDROPS® Achieves Clinical Safety and Efficacy Milestone

ByConnor Hodde

EyeCRO is thrilled to announce the first clinical application of our groundbreaking MiDROPS® technology. This marks a pivotal moment in eye care, leveraging our innovative delivery system to enhance the effectiveness of treatments for eye diseases, beginning with the notable success of Telios Pharma’s TL-925 for dry eye disease.1 Read the official press release.

Pioneering with MiDROPS®

EyeCRO has a vision to transform eye care, making treatments more accessible and effective. The MiDROPS® technology was developed with this goal in mind, offering a novel way to deliver medications directly to the eye via topical installation. By optimizing the formulation and delivery, MiDROPS® promises to increase the bioavailability of treatments, ensuring patients receive the full therapeutic benefit.

Clinical Triumph of TL-925

The collaboration with Telios Pharma represents a significant milestone in utilizing MiDROPS® for their clinical trials of TL-925, a novel treatment aimed at combating the challenges of dry eye disease.2 These trials have unveiled groundbreaking results, showcasing TL-925’s ability to rapidly alleviate symptoms of moderate to severe dry eye disease with remarkable efficacy. Patients participating in the TL-925 study experienced significant improvements, highlighting the potential of this groundbreaking treatment.

Looking Ahead: The Future of Eye Care with MiDROPS®

This initial success is just the beginning; EyeCRO envisions a future where ophthalmologists are empowered with an arsenal of MiDROPS®-based medications available to custom tailor their clinical treatment programs. Our commitment to innovation and patient care continues to drive us forward, with the goal of bringing more effective, patient-friendly solutions to the forefront of eye health. The positive outcomes of the TL-925 trials are a testament to the potential of combining innovative drug formulations with advanced delivery systems like MiDROPS®. For more detailed insights into our cutting-edge technology and to explore how we can enhance your eye therapy solutions, we invite you to contact us.

MiDROPS
  1. Telios Pharma Announces Successful Phase 2 Results for TL-925, a Novel Treatment for Dry Eye Disease. Press release; March 6, 2024. Accessed March 27, 2024. https://www.businesswire.com/news/home/20240305038505/en/Telios-Pharma-Announces-Successful-Phase-2-Results-for-TL-925-a-Novel-Treatment-for-Dry-Eye-Disease ↩︎
  2. A Study of TL-925 as a Treatment for Dry Eye Disease. ClinicalTrials.gov. Updated November 18, 2023. Accessed March 27, 2024. https://clinicaltrials.gov/study/NCT05745064 ↩︎

Similar Posts

Lab-Grown Retina from Stem Cells Responds to Light

ByConnor Hodde

…stem cell researchers have struggled to coax the malleable cells to form the 10 layers of the retina. And, crucially, no one had, before now, produced lab-grown retinal cells that they demonstrated would respond to light.Researchers at Johns Hopkins pulled it off, they reported in a paper published recently in Nature Communications. They cultivated a…

Scientists Develop Animal Model for TB-Related Blindness

ByConnor Hodde

Tuberculosis experts at Johns Hopkins and elsewhere have closely mimicked how active but untreated cases of the underlying lung infection lead to permanent eye damage and blindness in people.Lead study investigator and Johns Hopkins infectious disease specialist Petros Karakousis, M.D., says the new animal model should hasten development of a badly needed, early diagnostic test…

Study Findings Help Design Next-Generation Nanocarriers

ByConnor Hodde

Researchers believe that atomic-scale design of pharmaceuticals will be instrumental in producing more accurate and efficient drugs. Nanocarriers are engineered particles capable of holding tiny molecules inside their hollow interiors. Antibodies, which are bonded to the outer surface of these nanocarriers, function as markers to target specific cells or tissues or supply drugs to infected…

Scientists See New Hope for Restoring Vision With Stem Cell Help

ByConnor Hodde

Human-derived stem cells can spontaneously form the tissue that develops into the part of the eye that allows us to see, according to a study published by Cell Press in the 5th anniversary issue of the journal Cell Stem Cell. Transplantation of this 3D tissue in the future could help patients with visual impairments see…

Spark Surges in IPO as Prices Fuel Gene Therapy

ByConnor Hodde

Spark Therapeutics Inc. hit a $1.2 billion valuation on the biotechnology firm’s first day on the market, reflecting growing investor enthusiasm for the once-beleaguered field of gene therapy, a field that has produced the first $1 million drug.  The treatments focus on diseases where a single mutation in the genetic code is known to be…

iPad Vision Test Big Hit With Macular Degeneration Patients

ByConnor Hodde

An overwhelming majority of people with age-related macular degeneration would rather test their vision with an iPad app than with traditional methods, a new study shows. “One of the major advantages of iPad testing is that patients are much more involved in their disease. They’re engaged,” Matthias Hartmann, MD, an ophthalmologist in private practice from…